Introduction

Klippel-Trenaunay Syndrome (KTS) is an extremely rare congenital condition characterised by vascular malformations and abnormal growth of bones and soft tissues. First recognised in 1900 by French physicians Maurice Klippel and Paul Trenaunay, this syndrome affects approximately 1 in 100,000 people.1 While the underlying cause remains unclear, it appears to arise from genetic mutations leading to abnormalities in blood vessels and tissue development during fetal growth. KTS can manifest in myriad ways, often presenting challenges in diagnosis and management.2

Causes of Klippel-Trenaunay syndrome

The precise etiology and pathogenesis of KTS are not definitively known. However, current theories propose that genetic mutations influencing angiogenesis (blood vessel formation) during embryonic development lead to the vascular anomalies seen in KTS.

Somatic mosaic mutations in the PIK3CA gene involved in a signaling pathway are hypothesized to play a role. This pathway regulates cellular functions like proliferation, growth, apoptosis, metabolism, motility, and angiogenesis. Dysregulation of PIK3CA is believed to drive the overgrowth features of KTS by disrupting normal developmental angiogenesis and lymphangiogenesis.

The mutations likely occur sporadically in utero rather than being inherited. Environmental factors like placental insufficiency, maternal nutrition, infections, or teratogens during pregnancy may also impact the risk, although this link has not been firmly established. The origin appears to stem from a complex interplay of somatic genetic changes, dysregulated molecular signaling, and possibly environmental factors that disrupt normal vascular and lymphatic patterning.3

Further research is needed to clarify the precise etiologic factors.

Signs and symptoms of Klippel-Trenaunay syndrome

The clinical presentation of KTS can vary greatly, but most affected individuals present with some combination of the following signs and symptoms:

Port-Wine Stain Birthmarks

These flat, pink to reddish-purple macular skin lesions are present at birth and represent localized capillary vascular malformations in the superficial dermis. They typically occur on the limbs, especially the lower legs, but may also appear on the face, trunk, or other regions. The stains reflect the underlying anomalous development of capillaries and postcapillary venules, which become abnormally dilated due to impaired sympathetic innervation. The lesions tend to darken and thicken over time gradually.4

Varicose Veins

Abnormally dilated, tortuous superficial veins are another hallmark of KTS. They frequently emerge during childhood or puberty, becoming extensive and pronounced by adulthood. Varicose veins commonly affect the lower limbs but may also involve the arms, trunk, head, and neck. They result from the abnormal vascular anatomy and impaired venous return associated with KTS. Varicosities can cause pain, aching, cramping, swelling, discolouration, and recurrent thrombophlebitis.4

Limb Hypertrophy

Asymmetric overgrowth or hypertrophy of bones, muscles, and subcutaneous tissues in the arms or legs is characteristic of KTS. This gradually develops and progresses with age, often becoming noticeable as the child grows. The lower limbs are most frequently impacted, but upper limb involvement occurs in some patients. Limb overgrowth arises from the underlying venous and lymphatic dysplasia, which causes chronic oedema, stimulating cellular hyperplasia and tissue expansion. The discrepancy in limb size can be considerable.4

Vascular Malformations

In addition to varicosities, some individuals develop more complex low-flow vascular anomalies such as venous, lymphatic, or capillary malformations. High-flow arteriovenous malformations involving direct artery and vein connections may also occur but are less common. These can lead to massive shunting, vascular steal, high-output heart failure, and bleeding if severe. Cystic lymphatic malformations may cause pronounced lymphedema and swelling.4

Visceral Involvement

In approximately 10-15% of cases, KTS affects other organ systems beyond the limbs. Manifestations may include gastrointestinal bleeding from intestinal telangiectasias, hematuria from bladder involvement, scoliosis, spinal column overgrowth, pelvic bony asymmetry, and limb length discrepancy. There may also be genitourinary anomalies, renal agenesis, or the formation of arteriovenous malformations in organs like the liver, intestines, or brain.4

Psychosocial Challenges

The cosmetic effects and functional impairments stemming from KTS often significantly affect mental health and quality of life. Social anxiety, depression, poor self-esteem, and withdrawal are common due to disfigurement concerns and chronic pain. Support groups and counselling help patients cope adaptively.4

Bleeding Complications

Due to the fragility of vessel anomalies, patients may experience recurrent bleeding episodes, including gastrointestinal hemorrhage from intestinal vascular malformations, hematuria from bladder lesions, and bleeding into joint spaces from intra-articular hemangiomas. Anaemia is common.4

Associated Complications

Several debilitating complications can arise from KTS that diminish the quality of life:5

Chronic pain, infections, and ulcerations from varicose veins or vascular malformations in the skin and subcutaneous tissues

Joint pain, decreased mobility, degenerative arthritis and joint contractures resulting from limb length discrepancies, pelvic asymmetry, and asymmetric overgrowth of bones and soft tissues

Significant lymphedema, weeping lymphorrhea, and pronounced swelling due to impaired lymphatic drainage in the affected limb(s). This exacerbates pain, mobility problems, and the risk of cellulitis

Recurrent pulmonary emboli from deep vein thrombosis arising from venous stasis and endothelial damage in varicose veins. This is a leading cause of morbidity and mortality

Orthopedic deformities such as severe scoliosis, limb length discrepancy >2 cm, hip dysplasia, and joint subluxations secondary to bony/soft tissue overgrowth

Impaired wound healing and tissue breakdown due to chronic oedema and diminished tissue perfusion

Hemorrhagic complications like gastrointestinal bleeding, hematuria, and hemarthrosis, which can be recurrent

High-output cardiac failure resulting from extensive arteriovenous shunting and increased circulatory return

Careful monitoring and multidisciplinary management of symptoms aim to minimise complications and severity over time. However, the associated morbidity remains substantial.

Diagnostic Evaluations

Diagnosing KTS requires a high index of clinical suspicion coupled with confirmatory imaging studies. Key aspects of the evaluation include the following.

Detailed History and Physical Exam

The symptom onset and progression pattern provide clues as manifestations emerge over time. Medical history, pregnancy details, and family history are obtained, although KTS is sporadic. Evidence of port wine stains, varicosities, or limb size discrepancies on the exam helps identify KTS.6

Color Duplex Ultrasonography

This modality uses real-time imaging of tissues plus Doppler flow studies. It helps identify venous/lymphatic abnormalities and arteriovenous malformations while assessing circulation and flow velocities. Limb symmetry is also evaluated.6

MRI and CT Imaging

Magnetic resonance angiography (MRA) provides detailed 3D visualisation of vascular anatomy, limb musculature, overgrowth patterns, and skeletal anomalies without ionising radiation. CT imaging further delineates bony abnormalities and possible pelvic or abdominal organ involvement.6

Lymphoscintigraphy

Tracking lymphatic drainage in the limbs using radioactive tracers injected intradermally followed by gamma camera imaging. This helps detect lymphatic hypoplasia or hyperplasia.6

Tissue Biopsy

Skin or lesional biopsies may sometimes be pursued to assess for malignant transformation if new lesions appear. But the risks may outweigh the benefits.6

Molecular Genetic Testing

Commercial and research labs now offer targeted testing for PIK3CA mutations and other relevant genes. This can confirm the diagnosis but is not required.6

The constellation of clinical and imaging findings can definitively establish the diagnosis. KTS must be distinguished from other overgrowth disorders].

Management and treatment for Klippel-Trenaunay syndrome

As there is no cure for KTS, treatment focuses on early intervention to prevent complications, control symptoms, and preserve function. Individualised management strategies may include:

Compression Garments

Prescribed compression stockings, sleeves, or wraps promote venous/lymphatic return and reduce the risk of oedema, pain, and thrombosis. Gradient compression may help slow limb overgrowth.7

Medications

Blood thinners like low-dose aspirin or anticoagulants to reduce thromboembolism risk

Liposuction may help reduce limb size, contour deformities, and joint misalignment

Analgesics and anti-inflammatories provide pain relief

Antibiotics treat recurrent cellulitis

Vascular endothelial growth factor inhibitors (sorafenib, sirolimus) are being explored for complication prevention

Sclerotherapy

Injecting liquid or foam sclerosants into malformed veins damages the endothelium, causing them to shrink or close off. This reduces venous congestion. Often used for venous malformations not involving arteries.7

Embolisation

Interventional radiology can selectively block abnormal vascular structures and arteriovenous malformations through coiling or sclerotherapy. Prevents massive shunting.7

Surgical Interventions

Operations to debulk or contour enlarged limbs, excise problematic vascular growths, release joint contractures, reconstruct knee or ankle joints, and lengthen tendons/muscles to improve function. Orthopaedic procedures are done to correct bone/spine deformities.7

Laser Therapy

Using pulsed dye, YAG, or CO2 lasers to treat port-wine stain lesions for cosmetic reasons.7

Physical/Occupational Therapy

Prescribed exercises, gait training, splints, compression garments, and orthotic devices help maintain optimal mobility, function, and joint alignment.7

Psychological Support

Support groups, counselling, cognitive-behavioural therapy, and anti-depressant medications help patients cope adaptively with emotional distress and body image concerns.7

Treatment plans are highly tailored based on each patient's manifestations to provide symptomatic relief and curb progression. Monitoring for new or worsening complications is vital.

Emerging Medical Therapies

Several promising medical therapies are emerging for KTS, including:8

Sirolimus - An mTOR inhibitor that may counteract abnormal angiogenesis and overgrowth

Propranolol - A beta blocker being trialled to reduce port-wine stain extent and brightness

Sildenafil is a phosphodiesterase inhibitor used to treat lymphatic malformations and lymphedema by promoting lymphangiogenesis

Bevacizumab - A monoclonal antibody that blocks VEGF signalling and may decrease swelling and pain

Rapamycin - This immunosuppressant is also an mTOR inhibitor that can potentially inhibit pathological angiogenesis

Beta-blocker Creams - Topical timolol maleate preparations are being investigated for port-wine stain treatment

These medications offer promising options to supplement current interventional approaches. Larger-scale clinical trials are needed to validate safety and efficacy

Associated Risk Factors

KTS is a sporadic disorder, and currently, no specific genetic, epigenetic, or environmental risk factors have been firmly identified. The somatic PIK3CA mutations appear random rather than inherited.

Some data suggest that excess vascular endothelial growth factor (VEGF) or placental insufficiency during fetal development may play a role, but the findings are inconclusive.

There are no established lifestyle, dietary, or exposure risks that predispose to KTS - it remains unpredictable at this time.9

Prognosis and Long-Term Outcomes

The prognosis for individuals with KTS depends greatly on the severity of symptoms and associated complications. With astute clinical monitoring, compressive therapy, medications, and surgery when needed, many patients can enjoy a good quality of life.

However, potential impacts on mobility, chronic pain, bleeding risks, cardiac status, and psychosocial health must be addresse. Patients with minimal manifestations and no high-output cardiac failure can live normal life span.

Lifelong surveillance is imperative to screen for cancers and new vascular anomalies that could impact health.10

Emerging Research and Future Directions

Current research on KTS is focused on:

Elucidating the underlying genetic mechanisms through exome/genome sequencing and epigenetic approaches. This can identify contributory genes beyond PIK3CA

Developing animal models to study disease pathogenesis and trial novel treatments

Further investigating anti-angiogenic and lymphangiogenic therapies like sirolimus, beta-blockers, and VEGF inhibitors

Optimizing surgical techniques for debulking enlarged limbs, excising severe vascular malformations, and reconstructing joint deformities

Exploring newer sclerotherapy agents, embolisation materials, and laser technologies

Robust clinical trials to better define long-term outcomes with available treatments

Research on psychosocial impacts, quality of life, and mental health interventions

These efforts will provide tremendous insights into the pathology of KTS while enabling refinements in diagnostic and treatment modalities that can dramatically improve patient care, function, and quality of life.10

Conclusion

Klippel-Trenaunay Syndrome is a multifaceted congenital disorder with complex and variable clinical manifestations that emerge and progress over the patient's lifetime. Early recognition and diagnosis, close monitoring, and individually tailored treatment are essential to optimizing outcomes and quality of life. A coordinated multidisciplinary management approach that addresses physical symptoms and psychosocial health holds the most promise. While lifelong and often challenging, recent medical advances offer greater hope for those with KTS. Increased research promises to shed further light on this rare condition and open avenues for more effective diagnostic and therapeutic strategies that substantially improve prognosis and long-term well-being.

REFERENCES

Turner VL, Kearns C, Wattamwar K, McKenney AS. Klippel-trenaunay syndrome. RadioGraphics [Internet]. 2022 Oct [cited 2024 Jul 30];42(6):E167–8. Available from: http://pubs.rsna.org/doi/10.1148/rg.220150

Benson E, Chen H, Nakhosteen A, Yoong W. Management of postpartum haemorrhage in a patient with Klippel-Trènaunay syndrome. BMJ Case Rep [Internet]. 2022 Feb [cited 2024 Jul 30];15(2):e246601. Available from: https://casereports.bmj.com/lookup/doi/10.1136/bcr-2021-246601

Mahendra, Gosaliya., Jitendra, Kumar, Aloria., Rajesh, Goel., Dinesh, Kumar, Bairwa., Mohit, Maheshwari., Sachin, Pachori. Klippel–Trénaunay Syndrome (KTS or KT) is a rare clinical syndrome. Journal of Orthopaedics and Spine [Internet]. 2022 Jan [cited 2024 Jul 30];10(1):e43085. Available from:10.4103/JOASP.JOASP_53_21

Harnarayan P, Harnanan D. The klippel-trénaunay syndrome in 2022: unravelling its genetic and molecular profile and its link to the limb overgrowth syndromes. VHRM [Internet]. 2022 Apr [cited 2024 Jul 30];Volume 18:201–9. Available from: https://www.dovepress.com/the-klippel-trnaunay-syndrome-in-2022-unravelling-its-genetic-and-mole-peer-reviewed-fulltext-article-VHRM

Nyodu T, Pal S, Gayen K, Nanmaran P, Sarkar S. Klippel-trenaunay syndrome: A pedodontist perspective. J Prim Care Dent Oral Health [Internet]. 2022 [cited 2024 Jul 30];3(2):50. Available from: https://journals.lww.com/10.4103/jpcdoh.jpcdoh_43_21

Nguyen DA, Patel P, Weis SE. Delayed diagnosis of klippel-trénaunay syndrome in a 23-year-old african american male. HCA Healthcare Journal of Medicine [Internet]. 2022 Jun 30 [cited 2024 Jul 30];3(3). Available from: https://scholarlycommons.hcahealthcare.com/hcahealthcarejournal/vol3/iss3/16

Ibrahim MI, Hussain Awan L, Khan B, Javed K, Mariam Zehra S, Hussain M. Klippel-trenaunay-weber syndrome – a rare case with visceral manifestation and thrombosed marginal vein of servelle. PAFMJ [Internet]. 2022 Jul 8 [cited 2024 Jul 30];72(3):1142–3. Available from: https://www.pafmj.org/index.php/PAFMJ/article/view/6694

Klippel-trenaunay syndrome complicated with scrotal lymphedema: a rare entity not to be ignored. WJCMI [Internet]. 2022 Jul 7 [cited 2024 Jul 30];1(1). Available from: https://www.opastpublishers.com/open-access-articles/klippeltrenaunay-syndrome-complicated-with-scrotal-lymphedema-a-rare-entity-not-to-be-ignored.pdf

Tatakis A, Bowder A, Fraser S, Hohenwalter E, Malinowski M. Modern treatment of a Klippel–Trenaunay syndrome patient with Palma procedure. Vascular [Internet]. 2023 Mar 9 [cited 2024 Jul 30];170853812311618. Available from: http://journals.sagepub.com/doi/10.1177/17085381231161852

Karunamurthy A, Pantanowitz L, Lepe JG, Reyes-Múgica M. Lethal outcomes in klippel-trenaunay syndrome. Pediatr Dev Pathol [Internet]. 2013 Sep [cited 2024 Jul 30];16(5):337–42. Available from: http://journals.sagepub.com/doi/10.2350/13-03-1312-OA.1